AbbVie's first full year as an independent pharma company is on the books, and the fast-growing drug that has buoyed it from the start continues to churn out sales growth. Once again, Humira revenues made double-digit gains, driving a fourth-quarter profit that matched analysts' expectations.
What is better than having the best-selling drug in the world.? Having the best-selling drug and seeing its sales sprint ahead by more than 19% for a quarter.
AbbVie has whipped out the checkbook to close a partnership with Belgian antibody specialist Ablynx on one of its lead programs, paying $175 million upfront and promising up to $665 million more in milestones in exchange for a next-gen approach to rheumatoid arthritis that could eventually succeed Humira.
Humira is the world's best-selling drug, bringing in $9.6 billion last year. The way drug information specialist EvaluatePharma sees it, AbbVie's ($ABBV) gem is going to remain the...
The Cranbury, NJ-based biotech says they will focus on knockoffs of Humira, Rituxan, Avastin, Herceptin and Erbitux.
Revenues were up, net earning were down and the world's leading seller right now, Humira, continues to pull off some significant sales growth. That is the short version of the first-ever second-quarter earnings report for Big Pharma's newest player, AbbVie.
The regulators have spoken on both sides of the Atlantic. And in both cases, we have winners--and we have losers.
AbbVie's rheumatoid arthritis drug Humira did exactly what the new company needed it to do in the first quarter. It returned significantly higher sales and allowed Abbvie to report better than expected earnings in its first earnings report as a stand-alone company.
Pfizer has big expectations for its oral rheumatoid arthritis treatment Xeljanz--about $3 billion worth. But those expectations were struck a serious blow when European Medicines Agency regulators Thursday turned it down for approval.
Late last year Lonza and Teva sent a chill down the backs of an emerging group of developers working on biosimilars--those follow-on therapies that are expected to take the price of aging biologics down a peg or two as they lose patent protection.